Exploring the potential of antimalarial nanocarriers as a novel therapeutic approach

Nanostructured carrier systems facilitating enhanced delivery of 8-(4-Amino-1 methylbutylamino)-6 methoxyquinoline: a narrative review

“…By incorporating stimuli-responsive or biodegradable components into the carrier design, researchers can engineer systems that release AMBQ in a controlled manner in response to specific triggers or over extended periods [23,24] . This sustained-release capability not only ensures a consistent drug concentration within the therapeutic window but also enhances patient compliance and convenience, ultimately improving treatment outcomes and quality of life [25][26][27][28][29] . Moreover, interdisciplinary collaborations between researchers, clinicians, and industry stakeholders will be pivotal in translating these technological advancements into clinically viable solutions that address unmet medical needs [30][31][32][33][34][35][36] .…”

Advancing liposome technology for innovative strategies against malaria

“…Currently, antimalarial liposome formulations are being developed for various routes of administration, including parenteral, oral, and transdermal routes. However, most clinically tested liposome formulations are intended for intravenous or intramuscular administration in the form of sterile suspensions or lyophilized powders ( Deshmukh, 2023 , Hou et al, 2022 ).…”

“…Liposomes have also been investigated as adjuvants in malaria vaccines when administered intravenously. This strategy involves encapsulating synthetic peptide antigens and vaccines within liposomes to activate MHC class I and II pathways, stimulating cellular immune responses and antibody production ( Deshmukh, 2023 , Santos-Magalhães and Mosqueira, 2010 ). The transdermal route of administration provides an alternative for antimalarial drug delivery, offering advantages such as bypassing first-pass metabolism, ease of use, and the ability to discontinue therapy promptly.…”